From Acid Alpha-Glucosidase Deficiency to Autophagy: Understanding the Bases of POMPE Disease.

Pompe disease (PD) is caused by mutations in the GAA gene, which encodes the lysosomal enzyme acid alpha-glucosidase, causing lysosomal glycogen accumulation, mainly in muscular tissue. Autophagic buildup is considered the main factor affecting skeletal muscle, although other processes are also involved. Uncovering how these mechanisms are interconnected could be an approximation to address long-lasting concerns, like the differential skeletal and cardiac involvement in each clinical phenotype. In this sense, a network reconstruction based on a comprehensive literature review of evidence found in PD enriched with the STRING database and other scientific articles is presented. The role of autophagic lysosome reformation, PGC-1α, MCOLN1, calcineurin, and Keap1 as intermediates between the events involved in the pathologic cascade is discussed and contextualized within their relationship with mTORC1/AMPK. The intermediates and mechanisms found open the possibility of new hypotheses and questions that can be addressed in future experimental studies of PD.

The landscape of CRISPR/Cas9 for inborn errors of metabolism.

Since its discovery as a genome editing tool, the clustered regularly interspaced short palindromic repeats and CRISPR-associated protein 9 (CRISPR/Cas9) system has opened new horizons in the diagnosis, research, and treatment of genetic diseases. CRISPR/Cas9 can rewrite the genome at any region with outstanding precision to modify it and further instructions for gene expression. Inborn Errors of Metabolism (IEM) are a group of more than 1500 diseases produced by mutations in genes encoding for proteins that participate in metabolic pathways. IEM involves small molecules, energetic deficits, or complex molecules diseases, which may be susceptible to be treated with this novel tool. In recent years, potential therapeutic approaches have been attempted, and new models have been developed using CRISPR/Cas9. In this review, we summarize the most relevant findings in the scientific literature about the implementation of CRISPR/Cas9 in IEM and discuss the future use of CRISPR/Cas9 to modify epigenetic markers, which seem to play a critical role in the context of IEM. The current delivery strategies of CRISPR/Cas9 are also discussed.

Metabolic impact of infant formulas in young infants. An outlook from the urine metabolome.

Introduction: Although breast milk is the ideal food source for newborns during the first six months of life, a high percentage of children receive infant formulas. There is evidence that specific diet habits may influence individual metabolic profile. Therefore, in newborns, such profile can be influenced by the use of infantile formulas given the composition differences that display compared to human milk. Up to now, there are no reports in the literature that address this issue. Objectives: this work aims to compare the metabolic profile of full-term newborns that were feed with either breast milk (n = 32) or infantile formulas (n = 21). Methods: Metabolic profile was established based on urine analysis through gas chromatography-mass spectrometry (GC-MS) and nuclear magnetic resonance (H-NMR). Results: our results evidenced a more gluconeogenic profile in breast-fed infants characterized by elevation of Kreb's cycle intermediaries like fumaric, succinic and ketoglutaric acids compared to infants receiving infant formula. In addition, infant formula fed infants presented urinary excretion of metabolites derived from specific compounds present in this type of diet that were not observed in breast-fed infants, for instance D-glucitol, and 4-deoxytetronic. Moreover, in infant formula fed infants there was excretion of basal levels of metabolites of clinical relevance like 3-hydroxy-3-methyl-glutaric, 2-methyl-3-keto-valeric and 3,4-dihydroxybutyric. Conclusion: These results show the importance of understanding the metabolic impact of diet in newborn population in normal and pathological contexts.

Sphingolipids and their role in health and disease in the central nervous system.

Sphingolipids (SLs) are lipids derived from sphingosine, and their metabolism involves a broad and complex network of reactions. Although SLs are widely distributed in the body, it is well known that they are present in high concentrations within the central nervous system (CNS). Under physiological conditions, their abundance and distribution in the CNS depend on brain development and cell type. Consequently, SLs metabolism impairment may have a significant impact on the normal CNS function, and has been associated with several disorders, including sphingolipidoses, Parkinson's, and Alzheimer's. This review summarizes the main SLs characteristics and current knowledge about synthesis, catabolism, regulatory pathways, and their role in physiological and pathological scenarios in the CNS.

GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies.

GM2 gangliosidoses are a group of pathologies characterized by GM2 ganglioside accumulation into the lysosome due to mutations on the genes encoding for the ß-hexosaminidases subunits or the GM2 activator protein. Three GM2 gangliosidoses have been described: Tay-Sachs disease, Sandhoff disease, and the AB variant. Central nervous system dysfunction is the main characteristic of GM2 gangliosidoses patients that include neurodevelopment alterations, neuroinflammation, and neuronal apoptosis. Currently, there is not approved therapy for GM2 gangliosidoses, but different therapeutic strategies have been studied including hematopoietic stem cell transplantation, enzyme replacement therapy, substrate reduction therapy, pharmacological chaperones, and gene therapy. The blood-brain barrier represents a challenge for the development of therapeutic agents for these disorders. In this sense, alternative routes of administration (e.g., intrathecal or intracerebroventricular) have been evaluated, as well as the design of fusion peptides that allow the protein transport from the brain capillaries to the central nervous system. In this review, we outline the current knowledge about clinical and physiopathological findings of GM2 gangliosidoses, as well as the ongoing proposals to overcome some limitations of the traditional alternatives by using novel strategies such as molecular Trojan horses or advanced tools of genome editing.

Implementación de un método para la cuantificación de cistina intraleucocitaria como apoyo diagnóstico para la cistinosis / Implementation of an intraleukocitary cystine quantification method for diagnosis of cystinosis

ANTECEDENTES Y OBJETIVOS: La cistinosis es un error innato del metabolismo cuyas características clínicas incluyen compromiso renal severo y formación de cristales de cistina en la córnea, especialmente en la presentación adulta de la enfermedad. Es una enfermedad tratable, por lo cual establecer el diagnóstico de forma oportuna es fundamental para iniciar la terapia. Para la confirmación bioquímica de la enfermedad se requiere determinar las concentraciones intracelulares de cistina, para lo cual se han reportado diferentes métodos tanto para el aislamiento de las células como para la cuantificación del aminoácido. Con el objetivo de mejorar el diagnóstico bioquímico confirmatorio en nuestro medio establecimos un protocolo de cuantificación intraleucocitaria de cistina. MÉTODOS: Se implementó un método de cuantificación de cistina en polimorfonucleares por cromatografía líquida de alta resolución, evaluando el mejor anticoagulante a utilizar, la estabilidad de la muestra a 4̊ C y estableciendo valores de referencia para nuestra población. RESULTADOS: Se determinó que la muestra para cuantificación intraleucocitaria de cistina debe ser anticoagulada mediante la adición de ácido cítrico-dextrosa como anticoagulante. La muestra debe ser procesada inmediatamente, dada su baja estabilidad incluso en refrigeración. Con 50 individuos sanos se estableció como punto de corte para nuestra población 0,34 nmol 1/2 cistina/mg. CONCLUSIÓN: La adaptación realizada del método de cuantificación de cistina utiliza el número más alto de muestras control hasta ahora reportado en la literatura. Nuestros resultados dan cuenta de la necesidad de implementar el método a nivel local y reafirman la conveniencia de que cada laboratorio establezca sus propios valores de referencia para proporcionar una mayor confiabilidad a la hora de interpretar los resultados

Background and aims: Cystinosis is an inborn error of metabolism, clinically characterised by severe renal involvement and development of corneal cystine deposits, especially in the adult form of the disease. Cystinosis is a treatable condition. Therefore, an early diagnosis is necessary to start therapy. For biochemical confirmation of the condition it is necessary to quantify intracellular cystine concentrations. For this, different methods have been described with variations in cell isolation strategies and the amino acid quantification techniques used. In order to improve confirmatory biochemical diagnosis in our setting, a protocol for intraleukocitary cystine quantification was established. METHODS: A high performance liquid chromatography based method for cystine quantification in polymorphonuclear cells was implemented. Evaluation of the best anticoagulant to use and temperature stability of the sample at 4̊C were performed. In addition, we established reference values for our population. RESULTS: It was determined that intraleukocitary cystine quantification must be performed in blood samples containing acid-citrate-dextrose as anticoagulant. Samples must be processed immediately due to their poor stability even when refrigerated. Based on the results from 50 healthy individuals, the cut-off point established for our population was 0.34 nmol 1/2 cystine/mg. CONCLUSION: The adaptation performed to the cystine quantification method here presented the highest control population that has been reported in the literature so far. Our results highlight the need for making available a cystine quantification method locally and confirm the convenience for each laboratory to establish its own reference values to provide greater reliability for interpreting results

Implementation of an intraleukocitary cystine quantification method for diagnosis of cystinosis. / Implementación de un método para la cuantificación de cistina intraleucocitaria como apoyo diagnóstico para la cistinosis.

BACKGROUND AND AIMS: Cystinosis is an inborn error of metabolism, clinically characterised by severe renal involvement and development of corneal cystine deposits, especially in the adult form of the disease. Cystinosis is a treatable condition. Therefore, an early diagnosis is necessary to start therapy. For biochemical confirmation of the condition it is necessary to quantify intracellular cystine concentrations. For this, different methods have been described with variations in cell isolation strategies and the amino acid quantification techniques used. In order to improve confirmatory biochemical diagnosis in our setting, a protocol for intraleukocitary cystine quantification was established. METHODS: A high performance liquid chromatography based method for cystine quantification in polymorphonuclear cells was implemented. Evaluation of the best anticoagulant to use and temperature stability of the sample at 4̊C were performed. In addition, we established reference values for our population. RESULTS: It was determined that intraleukocitary cystine quantification must be performed in blood samples containing acid-citrate-dextrose as anticoagulant. Samples must be processed immediately due to their poor stability even when refrigerated. Based on the results from 50 healthy individuals, the cut-off point established for our population was 0.34nmol 1/2 cystine/mg. CONCLUSION: The adaptation performed to the cystine quantification method here presented the highest control population that has been reported in the literature so far. Our results highlight the need for making available a cystine quantification method locally and confirm the convenience for each laboratory to establish its own reference values to provide greater reliability for interpreting results.

Diagnóstico clínico y bioquímico del síndrome de leigh en cinco pacientes colombianos / Clinical and biochemical diagnosis of leigh syndrome in five colombian patients / Diagnóstico clínico e bioquímico da síndrome de leigh em cinco pacientes colombianos

Resumen El síndrome de Leigh (SL) es una enfermedad neurodegenerativa, descrita como una encefalomielopatía necrotizante subaguda, y es una de las enfermedades de origen mitocondrial más frecuentes. El SL es causado por el déficit en la producción de energía, originada en defectos en los genes que codifican alguno de los complejos mitocondriales; el gen afectado puede ser de codificación tanto nuclear como mitocondrial, lo que explica que se encuentren diferentes mecanismos de herencia, incluyendo autosómica recesiva y herencia materna, lo que, a su vez, hace más difícil su diagnóstico molecular. Clínicamente se presenta con regresión del desarrollo cognitivo y pérdida de habilidades motoras con trastorno de movimiento, de rápida progresión. El diagnóstico se basa en la demostración bioquímica de la elevación del ácido láctico y de la relación lactato/piruvato, así como hallazgos en las neuroimágenes por resonancia magnética que muestran lesiones focales, bilaterales y simétricas en ganglios basales o tallo cerebral asociadas a leucoencefalopatía y atrofia cerebral. Se reportan cinco casos con diagnóstico clínico y bioquímico del SL que ejemplifican la variabilidad clínica y gravedad encontrada en este grupo de pacientes.

Summary Leigh syndrome (LS) is a neurodegenerative disease, described as a subacute necrotizing encephalomyelopathy and is one of the most frequent diseases of mitochondrial origin. LS is caused by a deficit in the energy production due to defects in the genes that encode some of the mitochondrial complexes. The affected gene can be due to either nuclear and/or mitochondrial coding, which explains why there are different ways of inheriting the disease, including autosomal recessive and maternal inheritance, which makes its molecular diagnosis even more difficult. Clinically, LS is characterized by regression in cognitive development and motor abilities, as well as movement disorders of rapid progression. Its diagnosis is based on the biochemical demonstration of an increase in lactic acid and lactate / pyruvate ratio, as well as magnetic resonance neuroimaging findings showing focal, bilateral and symmetric lesions in basal ganglia or brainstem associated with leukoencephalopathy and cerebral atrophy. Five cases are reported with clinical and biochemical diagnosis of LS that exemplify the clinical variability and severity found in this group of patients.

Resumo A síndrome de Leigh (SL) é uma doença neurodegenerativa, descrita como uma encefalomielopatia necrotizante subaguda e é uma das doenças de origem mitocondrial mais frequente. A SL é causada pelo déficit na produção de energia originada em defeitos nos genes que codificam algum dos complexos mitocondriais; o gene afetado pode ser de codificação tanto nuclear como mitocondrial, o que explica que se encontrem diferentes mecanismos de herança, incluindo autossômica recessiva e herança materna, o que torna mais difícil seu diagnóstico molecular. Clinicamente se apresenta com regressão do desenvolvimento do desenvolvimento cognitivo e perda de habilidades motoras com transtorno de movimento, de rápida progressão. O diagnóstico se baseia na demonstração bioquímica da elevação do ácido láctico e da relação lactato/piruvato, assim como descobertas nas neuro imagens por ressonância magnética que mostram lesões focais, bilaterais e simétricas em gânglios basais ou talo cerebral associadas a leucoencefalopatia e atrofia cerebral. Reportam-se cinco casos com diagnóstico clínico e bioquímico da SL que exemplificam a variabilidade clínica e gravidade encontrada neste grupo de pacientes.

¿Tiene el paciente una leucodistrofia? Importancia de la descripción clínica, la semiología y las neuroimágenes ante la sospecha diagnóstica de leucodistrofia de origen metabólico / Does the patient have a leukodystrophy? Importance of clinical description, semiotics and neuroimaging in the diagnostic suspicion of a metabolicorigin leukodystrophy / O paciente tem uma leucodistrofia? Importância da descrição clínica, a semiótica e as neuroimagens ante a suspeita diagnóstica de leucodistrofia de origem metabólica

RESUMEN El enfoque de los errores innatos del metabolismo (EIM) constituye un desafío para cualquier especialidad médica y es un área en rápido desarrollo; a medida que se amplía la información científica, se fortalece el estudio de las enfermedades metabólicas y crecen la necesidad y el interés de hacer diagnósticos certeros y oportunos, de manera que sea posible comenzar el tratamiento apropiado lo más pronto posible. Es preciso usar un enfoque sistemático y ordenado que incluya todas las entidades clínicamente parecidas, desde las más frecuentes hasta las más raras, usando racionalmente los estudios más especializados y complejos, que, en general, son menos accesibles para el paciente. Presentamos el caso de una paciente con historia de noxa perinatal y alteraciones neurológicas cuyo curso clínico no progresó. Se resalta la importancia de un proceso diagnóstico sistemático que le dé prioridad al cuadro clínico.

SUMMARY The approach to inborn errors of metabolism (IEM) is a challenge for any medical specialty. This is a rapidly developing area. As scientific information expands, the study of metabolic diseases strengthens, and increases the need and interest in confirming or discarding such errors, in order to offer patients prompt and appropriate therapeutic alternatives. To achieve this, it is necessary to use a rational and orderly clinical approach that takes into account the possibility of an IEM, as well as other diseases resembling them. Also to rationalize the use of more specialized, and complex diagnostic aids, that generally are less accessible to the patient. We report the case of a patient with a history of perinatal noxa, and neurological disorders, whose clinical course did not progress. The importance of a systematic diagnostic process, based mainly on the clinical picture, is emphasized.

RESUMO A focagem dos erros inatos do metabolismo (EIM) constitui um desafio para qualquer especialidade médica e é uma área em rápido desenvolvimento; na medida que amplia-se a informação científica, fortalece-se o estudo das doenças metabólicas e crescem a necessidade e o interesse de fazer diagnósticos certeiros e oportunos, de maneira que seja possível começar o tratamento apropriado o mais rápido possível. É preciso usar uma focagem sistemática e ordenada que inclua todas as entidades clinicamente parecidas, desde as mais frequentes até as mais raras, usando racionalmente os estudos mais especializados e complexos, que, em geral, são menos acessíveis para o paciente. Apresentamos o caso de uma paciente com história de noxa perinatal e alterações neurológicas cujo curso clínico não avançou. Ressalta-se a importância de um processo diagnóstico sistemático que de prioridade ao quadro clínico.

Síndrome de Kearns Sayre: reporte de dos casos / Kearns Sayre Syndrome: Report of two cases

RESUMEN El síndrome de Kearns Sayre (SKS) es una rara mitocondriopatía causada en la mayoría de los casos por deleciones en el ADN mitocondrial, usualmente no heredada y de ocurrencia espontánea. Se caracteriza por disfunción multiorgánica de manifestación antes de los veinte años de edad. Fue descrito por Thomas Kearns y George Sayre, quienes reportaron la tríada de oftalmoplejía externa, retinopatía pigmentaria y bloqueos de la conducción cardíaca, siendo esta última alteración determinante en el pronóstico, así como el número de órganos afectados. Presentamos dos casos de Síndrome de Kearns Sayre con manifestaciones clínicas oftalmológicas en su debut, asociados a debilidad muscular, similar a los casos típicos reportados en la literatura, donde la mayoría de los pacientes presentan compromiso ocular. En la literatura colombiana existen pocos reportes de este síndrome, por lo tanto, esta presentación contribuye al conocimiento de la entidad en nuestro medio, la patología presenta una triada clínica específica, pero a la vez muestra una afección multisistémica que requiere un alto índice de sospecha por parte de las especialidades a las cuales el paciente puede acceder en su cuadro inicial.

SUMMARY The Kearns-Sayre syndrome is a rare mitochondrial disease caused, in most cases by deletions in mitochondrial DNA, usually not inherited and spontaneously occurring. It is characterized by multiorganic dysfunction that typically develops before the age of twenty. Described by Thomas Kearns and George Sayre who reported a case with presence of the triad of external ophthalmoplegia, pigmentary retinopathy and cardiac conduction blocks, the latter being decisive alteration in the forecast, as well as the number of affected organs. We report two cases of Kearns-Sayre syndrome debuting with ophthalmological clinical manifestations, associated with muscle weakness, similar to typical cases reported in the literature where most patients have eye involvement. The Colombian literature there are very few reported cases of this syndrome, so this presentation contributes to the knowledge of this entity in our environment, taking into account that this disease presents a specific clinical triad but both shows multisystem condition, requiring a high index of suspicion on the part of various specialties to which the patient can be accessed.

Acidemia glutárica tipo 1: presentación de un caso y revisión de la literatura / Glutaric acidemia type I. Report of a case and literature review / Acidemia glutárica tipo 1: apresentação de um caso e revisão da literatura

La acidemia glutárica tipo-1 es uno de los errores innatos del metabolismo diagnosticados con mayor frecuencia en Colombia. Es consecuencia de una alteración en el metabolismo de los aminoácidos lisina, hidroxilisina y triptófano, de la que resulta acumulación de ácidos glutárico y 3-hidroxiglutárico en los fluidos corporales. Clínicamente es un trastorno neurológico caracterizado por macrocefalia, atrofia cerebral progresiva y distonía. Por su evolución crónica es una enfermedad subdiagnosticada, de tal forma que pueden pasar varios años hasta que la sintomatología o las neuroimágenes sugieren la etiología metabólica. Sin embargo, algunos pacientes presentan la forma aguda usualmente desencadenada por una infección entre los 6 y 18 meses de edad. Por ser susceptible de manejo nutricional, es necesario hacer tempranamente el diagnóstico e iniciar el tratamiento, para prevenir o mejorar las complicaciones y enfermedades intercurrentes. Es de importancia considerar la AG-1 en el diagnóstico diferencial de pacientes con parálisis cerebral espástica o disquinética sin una historia clara de eventos hipóxicos, así como en pacientes con regresión en los hitos del neurodesarrollo. Se describe un caso con presentación aguda, que ilustra el curso clínico y el enfoque diagnóstico de la enfermedad.

Glutaric acidemia type I (GA-1) is a neurological disease of metabolic ethiology. Although considered rare, it is one of the most frequent inborn errors of metabolism in Colombia. GA-1 is caused by alterations in lysine, hydroxylysine and tryptophan metabolism, resulting in the accumulation of glutaric and 3-hydroxyglutaric acids in body fluids. Clinically, it is characterized by macrocephaly, progressive cerebral atrophy, and dystonia secondary to striatal degeneration. Due to its chronic evolution, it is usually under- diagnosed, so that several years may pass before suggestive symptoms or brain imaging findings are discovered. In some patients, the disease may appear acutely triggered by an infection between 6 and 18 months of age. Due to the availability of nutritional treatment, it is necessary to make an early diagnosis and to start treatment, in order to prevent or improve complications and associated diseases. It is important to consider GA-1 in the differential diagnosis of patients with spastic or dyskinetic cerebral palsy without a clear history of hypoxic events, as well as in patients with regression in neurological development. We report a case with acute presentation to exemplify the natural history of the disease and the diagnostic approach to it.

A Acidemia Glutárica tipo-1 é um dos erros inatos do metabolismo diagnosticados com maior frequência na Colômbia. É consequência de uma alteração no metabolismo dos aminoácidos lisina, hidroxilisina e triptófano, da que resulta acumulação de ácidos glutárico e 3-hidroxiglutárico nos fluidos corporais. Clinicamente é um transtorno neurológico caracterizado por macrocefalia, atrofia cerebral progressiva e distonia. Por sua evolução crônica é uma doença subdiagnosticada, de tal forma que podem passar vários anos até que a sintomatologia ou as neuroimagens sugerem a etiologia metabólica. No entanto, alguns pacientes apresentam a forma aguda usualmente desencadeada por uma infecção entre os 6 e 18 meses de idade. Por ser susceptível de manejo nutricional, é necessário fazer cedo o diagnóstico e iniciar o tratamento, para prevenir ou melhorar as complicações e doenças intercorrentes. É de importância considerar a AG-1 no diagnóstico diferencial de pacientes com paralisia cerebral espástica ou disquinética sem uma história clara de eventos hipóxicos, bem como em pacientes com regressão nas metas do neurodesenvolvimento. Descreve-se um caso com apresentação aguda, que ilustra o curso clínico e o enfoque diagnóstico da doença.

Human sulfatase transiently and functionally active expressed in E. coli K12

The recombinant human iduronate 2-sulfate sulfatase (hrIDS) was transiently and functionally active expressed in E. coli K12. The enzyme activity (crude extract) at 100 ml and 400 ml oscillated between 0.25 and 10.58 nmol h-1 mg-1. The wide Western-blot peptide profile suggest that hrIDS is proteolitically processed randomly which agrees with the ultrafiltration assay in which the hrIDS activity was found in all fractions (<30kDa, 30-100kDa and >100kDa). No glycation sites were found by computer analysis of the hIDS sequence; discarding the possibility of marks for glycation and proteolytic processing.

Uso de vectores derivados de virus adenoasociados para el tratamiento de la enfermedad de Morquio A / Adenoassociated virus-derived vectors for the treatment of Morquio A disease

En el desarrollo de una estrategia de terapia génica para la mucopolisacaridosis IV A (enfermedad de Morquio A), en el presente trabajo se evaluó la capacidad de un vector adenoasociado (AAV) para expresar el gen de la enzima sulfatasa N-acetilgalactosamina-6-sulfato (GALNS, N-acetylgalactosamine-6-sulfate sulfatase) en células HEK293, fibroblastos humanos con mucopolisacaridosis IV A y condrocitos de ratón con mucopolisacaridosis IV A. En el lisado celular, la actividad de la GALNS se incrementó entre 5 y 24 veces los valores observados en las células sin transfectar. La coexpresión con el gen del factor activador de sulfatasas 1 (SUMF1, sultatase modifiying factor 1) permitió un incremento en la actividad de la GALNS en el lisado celular de hasta 4,5 veces los valores observados en las células cotransfectadas con AAV-GALNS. La actividad de la GALNS en el medio de cultivo sólo se detectó en células cotransfectadas con AAV-SUMF1. Estos resultados constituyen evidencia valiosa sobre la posibilidad de realizar la corrección del defecto genético en la mucopolisacaridosis IV A empleando vectores AAV...

Toward the development of a gene therapy strategy for the mucopolysaccharidosis IV A (MPS IV A, Morquio A), in this work we evaluated the capability of an AAV vector to express the N-acetilgalactosamine-6-sulfate sulfatase (GALNS) gene in HEK293 cells, human mucopolysaccharidosis IV A fibroblasts and murine MPS IV A chondrocites. GALNS activity in lysated cells was increased between 5 and 24 folds compared to nontransfected cells. Also, the effect of coexpression with the sultatase modifiying factor 1 (SUMF1) was evaluated.GALNS activity was increased up to 4.5 folds in lysated cells compared to those values observed in AAV-GALNS transduced cells. Noteworthy, enzyme activity was only detected in culture media when cells were cotransfected with AAV-GALNS and AAV-SUMF1. These results represent a valuable step in the development of a gene therapy strategy for mucopolysaccharidosis IV A using AAV vectors...

Cuantificación de aminoácidos en plasma empleando Cromatografía Líquida de Alta Eficiencia / Plasma amino acid quantification using High Performance Liquid Chromatography

Las aminoacidopatías son errores innatos del metabolismo intermediario de los aminoácidos. Su confirmación diagnóstica y seguimiento se realiza con la cuantificación de aminoácidos libres en fluidos biológicos por técnicas como la cromatografía líquida de alta eficiencia (HPLC), para lo que es necesario comparar con valores de referencia normales. La población colombiana no cuenta con estos valores disponibles y el diagnóstico es realizado por comparación con los de otras poblaciones. En el presente trabajo se obtuvieron valores de referencia de aminoácidos en plasma en una población de niños (n=36) y adultos no afectados (n=17), mediante HPLC por derivatización postcolumna con ninhidrina. Los valores de referencia obtenidos fueron ligeramente más elevados que los informados para otras poblaciones y permitieron la identificación de doce casos de aminoacidopatías, incluyendo fenilcetonuria clásica, hiperfenilalaninemia, hiperglicinemia no cetósica, desórdenes del ciclo de la urea, tirosinemia. La implementación de la cuantificación de aminoácidos por HPLC y la obtención de los valores de referencia de aminoácidos en plasma permitirán aumentar el conocimiento sobre la incidencia de las aminoacidopatías en el país para garantizar, junto con otros factores, su diagnóstico preciso y oportuno y la implementación de un adecuado seguimiento nutricional.

Aminoacidopathies are inborn errors of the amino acid intermediary metabolism. The benchmark method used for their diagnosis and monitoring is the quanti!cation of free amino acids in biological fluids using High Performance Liquid Chromatography (HPLC), which needs to be compared against normal reference values. However, those amino acid reference values are not available for the Colombian population and the diagnosis is usually made using values from American or European populations. In this work, plasma amino acid reference values in non-affected children (n=36) and adults (n=17) were established, using an HPLC method with a postcolumn derivatization with ninhidrine. Plasma amino acid reference values in a Colombian population were slightly higher compared with those reported for other populations, and enabled the identification of twelve aminoacidopathies including urea cycle disorders, phenylketonuria, hyperphenylalaninemia, nonketotichyperglycinemia, hepatorrenaltyrosinemia and maple syrup urine disease. The implementation of amino acid cuantification by HPLC and the construction of plasma amino acid reference values is very useful for a suitable and precise diagnosis of amino acid disorders, the implementation of proper nutritional treatments, and an increased knowledge of aminoacidopathy incidence in Colombia.